Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

Preclinical Animal Research - Pulmonary Arterial Hypertension (PAH) Study

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This subcontract, managed by the Department of Health and Human Services for the NIH Office of the Director, involves conducting preclinical animal research focused on Pulmonary Arterial Hypertension. The project evaluates the therapeutic effects of soluble adenylyl cyclase inhibition on inflammatory vascular remodeling, utilizing wild-type controls and endothelial cell-specific Cav1 knockout murine models. The selected provider must possess specialized technical expertise in murine models of pulmonary hypertension and maintain strict compliance with federal animal welfare standards. The work will be performed in Chicago, Illinois, with the primary objective of delivering comprehensive research data and findings.

General Info

NIH subcontract for preclinical animal research on pulmonary hypertension in Chicago, Illinois.

Agency

Department Of Health And Human Services → National Institute Of Health Nih-OdView Agency

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)View NAICS

Place of Performance

Chicago, IL, 60607, USA

Set-Aside

NONE

Documents

This scope was carved out of 75N98026R00085.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

The Therapeutic Role of Soluble Adenylyl Cyclase Inhibition in Ameliorating Inflammatory Vascular Remodeling in Pulmonary Arterial Hypertension

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institute Of Health Nih-Od
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Health And Human Services → National Institute Of Health Nih-Od
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Performs preclinical animal research for prime contractors on NIH Office of the Director projects. Evaluates therapeutic effects of soluble adenylyl cyclase (sAC) inhibition on inflammatory vascular remodeling using endothelial cell-specific Cav1 knockout (EC-Cav1 KO) murine models and wild-type controls. Requires technical capability in murine models of pulmonary hypertension and compliance with federal animal welfare standards. Delivers research data and findings.

Similar Contracts

Same NAICS industry code

NAICS: 541715
New
Federal
The Therapeutic Role of Soluble Adenylyl Cyclase Inhibition in Ameliorating Inflammatory Vascular Remodeling in Pulmonary Arterial Hypertension
Solicitation # 75N98026R00085
The National Institutes of Health Office of the Director intends to award a firm-fixed-price purchase order to the University of Illinois at Chicago for preclinical animal research services. The project focuses on evaluating the therapeutic effects of soluble adenylyl cyclase inhibition on pulmonary arterial hypertension using an established endothelial cell-specific Cav1 knockout murine model and wild-type controls. The government is pursuing a sole-source acquisition under FAR 13.106-1(b)(1) because the University of Illinois at Chicago maintains the specific mouse colony required for the study, which is not known to be available from other laboratories. The scope of work involves 144 animals subjected to normoxia or chronic hypoxia and treated with sAC inhibitors KH7 or LRE1, both of which will be provided by the government. Required services include animal breeding, colony maintenance, genotyping, implantation of subcutaneous osmotic pumps, echocardiography, and right-heart catheterization. The contractor will also be responsible for necropsy and the preparation of lung and heart tissue for histological analysis, Western blotting, and RNA-seq. The anticipated period of performance is 12 months from the date of award, and the total value is not expected to exceed the simplified acquisition threshold. While the government intends to negotiate with a single source, responsible parties may submit capability statements and quotations by September 21, 2026.
National Institute Of Health Nih-Od

POSTED

1 day ago

DEADLINE

in 7 days
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 650+ contractors already using CLEATUS